ADHD drug – Cylert withdrawn from market due to Liver Toxicity, a Major Risk of Psychotropic Drugs Tue, October 25, 2005 The FDA announced that another drug prescribed for ADHD–Cylert–was removed from the US market for safety reasons. On September 25, 2005, the Associated Press reported: “Eli Lilly said it provided the FDA results from…

Read More

Pharma’s Pervasive Influence Corrupts Medicine both sides of Atlantic Tue, 4 Oct 2005 The focus of criticism in medicine has shifted from cost and barriers to access to treatments to an examination of the safety and benefit of current treatments. The pharmaceutical industry’s corrupting influence on physicians, academic researchers, the lay and professional journals, and…

Read More

Antidepressant Use in Children Soars Despite Efficacy Doubts – Washington Post Mon, 19 Apr 2004 A front page article by Shankar Vedantam in The Washington Post examines the soaring increase in the antidepressant drug prescriptions for children, noting: “The explosion in antidepressant use occurred even though the vast majority of clinical trials have failed to…

Read More

The Boston Globe reports (below): “More than 50 years after psychiatrists began widely dispensing drugs to treat mental illness, the profession is coming face to face with a humbling reality: Its treatments often fail, leaving millions of patients [  ] to suffer while doctors search for something that works.”

Read More

"Soon, intuition and the personal experience of friends and family may seem as trustworthy as advice from a doctor in diagnosing an illness or judging a treatment."

Read More

Big Pharma by Jacky Law reveals that in essence, most of the pharmaceutical industry’s claims are false; it is not the drug, but the placebo effect whose potency deserves almost all of the credit for any health improvement:

Read More

Two studies purporting to report “new encouraging” findings about the efficacy and safety of antidepressantsas tested in the “real world”were published on Sunday by The American Journal of Psychiatry with an accompanying editorial by Dr. Thomas Insel, director of these studies’ funding agency, the National Institute of Mental Health.

Read More